Overview

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib
Phase:
Phase 1
Details
Lead Sponsor:
Mirati Therapeutics Inc.